Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

mirikizumab-mrkz

mirikizumab-mrkz
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Omvoh INJECTION, INTRAVENOUS 20 mg/mL | 100 mg/mL      
Omvoh INJECTION, SUBCUTANEOUS 100 mg/mL | 200 mg/mL      
Comments:

Non-formulary. Use or initiation should be deferred to the non-hospital outpatient setting.  Alternative agents are available to treat ulcerative colitis in the outpatient setting.

 

Reviewed: May 2025

Mirikizumab-mrkz (OMVOH) Spotlight.pdf

Last updated: Jun. 12, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved